| 32.11 1.33 (4.32%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.6 | 1-year : | 48.59 |
| Resists | First : | 35.61 | Second : | 41.6 |
| Pivot price | 31  |
|||
| Supports | First : | 27.88 | Second : | 23.11 |
| MAs | MA(5) : | 30.27 |
MA(20) : | 31.21 |
| MA(100) : | 21.05 |
MA(250) : | 14.09 |
|
| MACD | MACD : | 0.7 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 46 |
D(3) : | 40 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 35.61 | Low : | 4.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FBRX ] has closed below upper band by 45.0%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.32 - 32.44 | 32.44 - 32.57 |
| Low: | 30.13 - 30.28 | 30.28 - 30.42 |
| Close: | 31.22 - 31.45 | 31.45 - 31.67 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Mon, 09 Feb 2026
Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan
Mon, 09 Feb 2026
Forte Biosciences Insider Ups Holding By 30% During Year - simplywall.st
Sat, 31 Jan 2026
Federated Hermes Inc. Acquires 563,147 Shares of Forte Biosciences, Inc. $FBRX - MarketBeat
Sat, 31 Jan 2026
Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5% - MarketBeat
Sun, 04 Jan 2026
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 96.8 (%) |
| Shares Short | 796 (K) |
| Shares Short P.Month | 139 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.1 % |
| Return on Equity (ttm) | -110.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -393.25 |
| PEG Ratio | 0 |
| Price to Book value | 6.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|